Financial Contrast: AIM ImmunoTech (NYSE:AIM) and LENZ Therapeutics (NASDAQ:LENZ)

AIM ImmunoTech (NYSE:AIM) and LENZ Therapeutics (NASDAQ:LENZ) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends and analyst recommendations.

Volatility and Risk

AIM ImmunoTech has a beta of 0.76, meaning that its stock price is 24% less volatile than the S&P 500. Comparatively, LENZ Therapeutics has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500.

Insider and Institutional Ownership

12.0% of AIM ImmunoTech shares are held by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are held by institutional investors. 0.0% of AIM ImmunoTech shares are held by insiders. Comparatively, 38.4% of LENZ Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares AIM ImmunoTech and LENZ Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AIM ImmunoTech	-12,594.21%	-421.73%	-147.54%
LENZ Therapeutics	N/A	-58.48%	-55.50%

Analyst Recommendations

This is a summary of recent ratings for AIM ImmunoTech and LENZ Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AIM ImmunoTech	0	0	2	0	3.00
LENZ Therapeutics	0	0	7	1	3.13

AIM ImmunoTech presently has a consensus target price of $2.75, suggesting a potential upside of 2,908.75%. LENZ Therapeutics has a consensus target price of $41.67, suggesting a potential upside of 96.73%. Given AIM ImmunoTech’s higher probable upside, equities analysts clearly believe AIM ImmunoTech is more favorable than LENZ Therapeutics.

Valuation & Earnings

This table compares AIM ImmunoTech and LENZ Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AIM ImmunoTech	$170,000.00	38.87	-$28.96 million	($0.31)	-0.29
LENZ Therapeutics	N/A	N/A	-$124.65 million	($4.77)	-4.44

AIM ImmunoTech has higher revenue and earnings than LENZ Therapeutics. LENZ Therapeutics is trading at a lower price-to-earnings ratio than AIM ImmunoTech, indicating that it is currently the more affordable of the two stocks.

Summary

LENZ Therapeutics beats AIM ImmunoTech on 8 of the 14 factors compared between the two stocks.

About AIM ImmunoTech

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

About LENZ Therapeutics

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.